Acadia Healthcare Company 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 revenue was $895 million, up 5.1% year over year; same-facility revenue increased 5.2%, driven by 1.1% growth in patient days and 4.0% growth in revenue per patient day.
- Consolidated adjusted EBITDA was $176.4 million, while same-facility adjusted EBITDA was $228.8 million, up 6.1% year over year; adjusted EPS was above management’s expectations.
- Acute revenue was $525 million, up 11% year over year, with acute volumes increasing 7.5% during the quarter; specialty revenue was $136 million, RTC revenue was $93 million, up 7%, and CTC revenue was $141 million, stable with the second quarter.
- The New York Medicaid program’s impact on Pennsylvania facilities reduced third-quarter same-facility revenue growth by approximately 1% and same-facility volume growth by approximately 2.6%.
- Acadia generated $98 million in operating cash flow and $47 million in free cash flow, repaid $63 million of debt, and ended the quarter with net leverage of approximately 3.9 times adjusted EBITDA.
- Acadia added 220 licensed beds in the quarter, including a 144-bed de novo acute facility near Jacksonville, Florida, and 76 beds at existing facilities; it opened 542 beds in 2026.
- Third-quarter adjusted EBITDA included a $13.4 million accrual for expected Florida Supplemental Payment Program payments for the year ended September 30th, 2026; additional contribution may be possible pending final approval.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Acadia Healthcare Third Quarter 2026 Earnings Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Jason Plagman, VP Investor Relations. Jason, please go ahead. Thank you and good morning.
Yesterday after the market closed, we issued a press release announcing our third quarter 2026 financial results. This press release can be found in the Investor Relations section of the acadiahealthcare.com website. Today, Debbie Osteen, Acadia's Chief Executive Officer, and David Duckworth, Interim Chief Financial Officer, will discuss the results. To the extent any non-GAAP financial measure is discussed in today's call, you will also find the reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP in the press release that is posted on our website. This conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements, among others, regarding Acadia's expected quarterly and annual financial performance for 2026 and beyond.
These statements may be affected by the important factors, among others, set forth in Acadia's filings with the Securities and Exchange Commission and in the company's third quarter news release, and consequently, actual operations and results may differ materially from the results discussed in the forward-looking statement. At this time, I would like to turn the conference call over to Debbie.
Good morning, and thank you for joining us. I'm pleased to be with you today to discuss Acadia's results for the third quarter of 2026. Acadia delivered strong results again this quarter that were ahead of our expectations as we continue to make progress on our key operational and financial priorities. As always, Acadia is guided by our mission to provide compassionate care that improves lives, inspires hope, and elevates communities. Our capabilities and the commitment of our employees allow us to stand as a leader in the behavioral healthcare industry through the important work we do. During the third quarter, we continued to execute on our key priorities: providing quality patient care, expanding access so we can provide care to a greater number of patients, delivering consistent operational excellence with strong financial discipline, and continuing to strengthen our leadership team throughout the company.
I'm pleased to say that our positive momentum continued in the third quarter. A few notable highlights include the following: We delivered revenue, adjusted EBITDA, and adjusted EPS that were above our expectations. We generated $47 million of free cash flow and reduced our debt by $63 million during the quarter. We opened our new 144-bed de novo acute facility near Jacksonville, Florida, in August. Coastal Pines Behavioral Health is our fourth new acute facility opening in 2023 and our 16th since the beginning of 2023. Our revenue in the third quarter increased 5.1% compared with the prior year period, driven by solid growth in patient volumes and strong revenue per patient day. We saw contributions to our growth from new facilities that we've opened over the last four years, as well as from legacy facilities. Same-facility revenue growth was 5.2%, which was at the high end of our expectations.
As I discussed last quarter, our team is operating with a strong sense of urgency and focus, and this has allowed us to accelerate timelines across multiple key milestones for our new facilities, including licensing, accreditation, and payer contracting. This is important because it allows us to begin to serve patients sooner, as well as accelerating contracting activities with commercial payers. All of the new facilities that were in our development plans are now open. Our team's focus and dedication enabled our new JV facilities, including Orlando Health and Methodist Jennie Edmundson, to move through the initial accreditation and licensure processes at a record pace for Acadia and much faster than in prior years. As we've discussed in prior quarters, we are focused on delivering more value from the investments we've made in our expanded bed capacity and the new facilities that we've opened over the last four years.
The positive momentum we are seeing in our new facilities that we've opened in 2023, as well as in 2023, 2024, and 2025, provides us with increasing confidence and visibility in our path to delivering on the $200 million of incremental adjusted EBITDA relative to 2025 that we've discussed previously. As a result, we expect to deliver approximately $60 million of incremental adjusted EBITDA from these cohorts in 2027 compared to 2026. This outlook is supported by our expectation for continued occupancy gains and strong fiscal discipline and efficiencies. We anticipate contributions from new facilities opened in the last 12 months as they move towards break-even, along with continued positive momentum from facilities that opened in earlier years. Overall, we continue to see strong demand for our services.
We are well-positioned to meet this demand with our expanded capacity and also through our initiatives aimed at providing patients with access to the full continuum of care, including our outpatient services that facilitate clinically appropriate step-downs to partial hospitalization and intensive outpatient programs. In addition to our strong financial performance, we are also focused on building an even stronger set of leaders across our organization through investments in internal talent development and collaboration, as well as targeted additions to the team. As an example, in August, we hosted an executive leadership summit that strengthened the connections and partnership between our facility CEOs, our corporate support teams, and our executive leadership team. We also continue to make meaningful progress advancing clinical quality, patient safety, and patient outcomes across Acadia.
During the third quarter, we expanded our measurement-based care initiatives across additional acute and specialty facilities, strengthening our ability to use patient-reported outcomes and other clinical data to guide treatment decisions and improve care. We remain focused on leveraging technology, analytics, and evidence-based practices to increase transparency into key quality metrics, support continuous improvement, and drive better outcomes for patients. I am also proud to share that Geisinger Behavioral Health Center Northeast was recognized with the Joint Commission’s inaugural Care Team Award. Joint Commission sets the standard for healthcare quality in the U.S., and its Care Team Award was established to recognize interdisciplinary teams that demonstrate exceptional collaboration, coordination, and patient-centered care. Geisinger Northeast is the first recipient of this national honor. Since opening in 2023, our team at Geisinger Northeast has built a culture where patient safety, quality, and experience are at the center of every decision.
We believe this award reflects Acadia’s commitment to safety, teamwork, and patient-centered care at Geisinger Northeast and across our entire organization. Overall, we have made significant progress on our key priorities so far this year, driven by our strong collaboration, execution, and sense of urgency. I am confident that we have the team and the capabilities in place to continue to drive Acadia forward and build on our momentum in the fourth quarter and beyond. With that, I will turn it over to David to review the financial details.
Thanks, Debbie, and good morning, everyone. Looking at our third quarter results, revenue of $895 million grew 5.1% compared to last year’s third quarter. Same facility revenue in the third quarter increased 5.2% on a year-over-year basis, driven by 1.1% growth in patient days and 4.0% growth in revenue per patient day. Similar to last quarter, the impact of changes in the New York Medicaid program on our Pennsylvania facilities reduced our third quarter same facility revenue growth rate by approximately 1% and our same facility volume growth by approximately 2.6%. Revenue in our acute business was $525 million in the third quarter and grew 11% on a year-over-year basis. We delivered strong acute volume and admissions growth in the third quarter from both legacy facilities and the new JV and de novo facilities that we have opened over the last four years.
Specialty revenue in the third quarter was $136 million, which represents positive growth compared to last year’s third quarter after normalizing for facility closures and the impact of changes in the New York Medicaid program on our Pennsylvania facilities. Looking at our RTC service line, revenue in the third quarter was $93 million and increased 7% year over year, driven by steady volume growth and growth in revenue per day. In our CTC business, third quarter revenue was $141 million, which was stable with the second quarter. Demand for CTC services remains solid, and we are seeing improving admissions trends in September and October related to some of the initiatives we have launched. Additionally, over the last few quarters, we have increased our operational efficiency and reduced our cost in the CTC service line.
Moving down the income statement, consolidated adjusted EBITDA for the third quarter was $176.4 million. On a same facility basis, adjusted EBITDA was $228.8 million in the third quarter and grew 6.1% compared to the prior year period. In terms of supplemental payments, during the third quarter, we recognized revenue and provider taxes related to Florida for the 2026 program year, consistent with our historical practice that we discussed last quarter. Third quarter adjusted EBITDA includes an accrual of $13.4 million for expected payments for the Florida supplemental payment program year ended September 30, 2026, which compares to $5.6 million included in our previous guidance. There may be additional contribution from the 2026 program year pending final approval. From a revenue cycle perspective, our bad debts and denials in the third quarter were stable as a percentage of revenue compared to the prior quarter.
As we moved through the quarter, we saw steady advances in our revenue cycle initiatives, and we anticipate continued progress in the fourth quarter. Outside of the same facility group, our losses from startup facilities were $12 million in the third quarter, which was slightly better than the midpoint of our expectations. For closed facilities, we had less than $1 million in operating losses during the quarter. Moving to the balance sheet and statement of cash flows, we remain in a solid financial position. Operating cash flow in the third quarter was $98 million, and capital expenditures were $51 million, resulting in free cash flow of $47 million. We repaid $63 million on our debt during the quarter, and our net leverage ratio, as defined in our credit agreement, stood at approximately 3.9 times adjusted EBITDA at the end of the quarter.
Looking at development, we added 220 licensed beds during the third quarter, which includes the opening of a 144-bed de novo facility near Jacksonville, Florida, as well as adding 76 beds to existing facilities. In total, we've opened 542 beds in 2026. Additionally, in the CTC service line, we opened one new clinic and closed one existing clinic during the quarter. With respect to capital expenditures, following a review of our ongoing and planned capital projects, we have reduced our full-year forecast for CapEx to a range of $210 million-$230 million.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
15 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
